Emmes calls in telehealth capabilities to expand eClinical platform

Preview

来源: FierceBiotech

Emmes has been busy in recent years, chalking up five acquisitions between 2021 and 2022.

Maryland-based CRO Emmes has added telehealth capabilities to its Advantage eClinical platform, allowing for virtual video calls for trial participants and sites.

The video option, which patients can use by signing into their existing portal, is part of Emmes’ plans to create a digital trial infrastructure that can accommodates all forms of clinical trials from on-site, decentralized, hybrid and fully virtual, the company said in a Sept. 27 press release.

The platform also has the capabilities for data capturing, cleaning and monitoring as well as managing workflow, sample tracking and clinical assessment and engagement tools.

“It's a platform to accelerate the delivery of all types of trial designs through one unified, modular system,” Ching Tian, Emmes’ chief innovation officer, said in the release. “By eliminating the need for sponsors to procure and set up additional point decentralized trial systems, we hope more studies will offer patient-centric options for patients to participate.”

Emmes has been busy in recent years, chalking up five acquisitions between 2021 and 2022. A year ago, it bought Clinical Edge, which offered training and certification of visual function examiners at investigator sites conducting ophthalmic clinical trials.

That followed the acquisition of Plymouth, Massachusetts-based rare disease trials contractor Casimir, U.K.-based rare disease specialist Orphan Reach, German late-phase study-focused contractor Institut Dr. Schauerte and Czech Republic-headquartered Neox.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。